Healthcare Industry News: dialysis
News Release - March 2, 2010
NxStage(R) and Dirinco Sign Distribution Agreement For System One(TM) in the NetherlandsLAWRENCE, Mass., March 2 (Healthcare Sales & Marketing Network) -- NxStage Medical, Inc. (Nasdaq:NXTM ), a leading manufacturer of innovative dialysis products, today announced that it signed a five-year distribution agreement with Dirinco, an independent company, for the promotion, sale, delivery and service of certain NxStage and Medisystems products in the Netherlands.
Under the terms of the agreement, the NxStage System One and PureFlow™ SL dialysate preparation system will be available to dialysis centers throughout the Netherlands exclusively through Dirinco. Dirinco will also make available the System One for use in critical care applications, and has the option to make NxStage Medisystems ButtonHole needles available to its customers in this region.
"We are pleased to announce this new opportunity to provide more patients access to our life-changing products while expanding our international presence," stated John Mullen, Vice President and General Manager, International, NxStage Medical, Inc. "We look forward to working closely with Dirinco, a company with a long history of successfully introducing new technologies and therapies to the Dutch market."
"As many dialysis patients in this region seek alternative treatments to in-center dialysis, we believe there is a real opportunity to advance home hemodialysis in the Netherlands," said Roel Kuiper, Managing Director of Dirinco. "Through our agreement with NxStage, our customers will gain access to this innovative technology and the quality of life and clinical benefits daily therapy with the System One has been reported to offer."
The Dutch Dirinco Group, with subsidiaries in Belgium and Switzerland (Citra-Lock), is a company, with innovative products and services mainly in the areas of chronicle and acute hemodialysis. Dirinco is a privately held company, with almost 25 years of experience in production and marketing of healthcare products. Over the years, Dirinco has become an expert in extracorporeal circulation treatment of renal failure. Today the company holds a leading position in the acute renal (CRRT) market in the Netherlands and supplies all Dutch dialysis clinics with several innovative products. Dirinco has strong relationships with nephrologists, intensivists, management, pharmacies and purchase departments of hospital organizations. The company has a direct Benelux sales and service organization and offers its innovations through a network of dedicated distributors to the remaining international markets.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq:NXTM ) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including Dirinco's ability to successfully promote, sell and service our products, customer demand for our products in the Netherlands, those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Source: NxStage Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.